---
title: "LBPMedicin released its 2024 annual performance, with a net profit attributable to the parent company of 21.2913 million yuan, a year-on-year decrease of 46.85%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236773170.md"
description: "LBPMedicin released its 2024 annual performance, with operating revenue of 471 million yuan, a year-on-year decrease of 5.33%; net profit attributable to the parent company of 21.2913 million yuan, a year-on-year decrease of 46.85%; net profit excluding non-recurring gains and losses of 14.2538 million yuan, a year-on-year decrease of 59.64%; basic earnings per share of 0.23 yuan/share. The company plans to distribute a cash dividend of 1.00 yuan (tax included) for every 10 shares"
datetime: "2025-04-21T11:12:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236773170.md)
  - [en](https://longbridge.com/en/news/236773170.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236773170.md)
generator: "portal-rs"
---

# LBPMedicin released its 2024 annual performance, with a net profit attributable to the parent company of 21.2913 million yuan, a year-on-year decrease of 46.85%

According to the Zhitong Finance APP, LBPMedicin (688393.SH) released its annual report for 2024, reporting an operating income of 471 million yuan for the year, a year-on-year decrease of 5.33%; net profit attributable to shareholders of the listed company was 21.2913 million yuan, a year-on-year decrease of 46.85%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 14.2538 million yuan, a year-on-year decrease of 59.64%; basic earnings per share were 0.23 yuan/share. It is proposed to distribute a cash dividend of 1.00 yuan (including tax) for every 10 shares

### Related Stocks

- [688393.CN](https://longbridge.com/en/quote/688393.CN.md)

## Related News & Research

- [US health agencies report 55 cases of E. coli and salmonella infections tied to alfalfa sprouts](https://longbridge.com/en/news/296645342.md)
- [REG - Aberdeen Asian Inc - Director/PDMR Shareholding](https://longbridge.com/en/news/296505605.md)
- [Vector Science files US provisional patent for orthopedic tissue-regeneration peptide platform](https://longbridge.com/en/news/296483037.md)
- [Cell C publishes pro forma financials after Comm Equipment Company merger](https://longbridge.com/en/news/296585930.md)
- [16:48 ETGI MAP Test Launches Cyclospora Guidance Service for Customers With a Detected Test Result](https://longbridge.com/en/news/296535077.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**